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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this
guideline.
The following are the recommendations of the American
College of Medical Genetics (ACMG) Professional Practice
and Guidelines Committee, which was convened to assist
health care professionals in making decisions regarding cyto-
genetic diagnostic testing and counseling for mental retarda-
tion (MR) and developmental delay (DD). This document re-
views available evidence concerning the value of conventional
and molecular cytogenetic testing for the identification of
chromosomalanomaliesthatplayaroleintheetiologyofMR/
DD,and,basedonthisevidence,specificrecommendationsfor
each method of testing are provided.
INTRODUCTION
Mental retardation (MR), defined by the World Health Or-
ganization (WHO) as an intelligence quotient (IQ)  70, is
characterized by significantly limited cognitive functioning,
coupledwithlimitationsinadaptiveskillsintwoormoreofthe
following areas: social skills, community living, communica-
tion, home living, health, self-direction, work, and leisure.1,2
MRisgenerallydividedintomild(IQof50-70),moderate(IQ
of35-50),andsevere(IQof20-35);thosecasesinwhichtheIQ
is below 20 are occasionally defined as profound.2,3 The prev-
alence rate of MR in the general population is estimated to be
approximately 1% to 3%, with mild MR occurring 7-10 times
more frequently than moderate or severe MR.2,4,5
Global developmental delay (DD) describes significant de-
lay in two or more of the following areas: cognition, speech/
language, gross/fine motor skills, social/personal skills, and
dailyliving.6DDisevidencedasage-specificdeficitsinlearning
skillsandadaptationincomparisonwithchronologicalpeers.6
BecausethediagnosisofMRrequiresaccurateandvalidassess-
ments of intelligence, the term DD is generally reserved for
children five years of age or younger, prior to the age at which
IQ testing can be applicable. Thus, a child with DD is not nec-
essarily destined to have MR. Several conditions, such as cere-
bralpalsy,someneuromusculardisorders,oradverseenviron-
mental effects, may result in early childhood learning delay,
though the child may test in the normal range for intelligence
when he or she is old enough to be accurately assessed. Like
MR, the prevalence rate of DD in the general population is
estimated to be 1 to 3%.6–10
The etiology of MR/DD is complex and may include environ-
mental factors, Mendelian disorders, and chromosomal abnor-
malities, presenting alone or in combination. The cause of
MR/DD can be identified in 40% to 60% of cases;1 however, the
percentage of mild MR/DD cases for which a cause can be estab-
lishedis24%,whichissignificantlylower.11Chromosomeabnor-
malities are the single most common cause found in series of un-
selected patients with MR/DD. Rates of identifying chromosome
abnormalities range from 15% to 40% in surveys of severe MR/
DD,withsubstantiallylowerratesformildMR/DD.11,12Further-
more, it is estimated that approximately 5% of MR/DD can be
attributed to chromosomal abnormalities in the subtelomeric
regions.13,14 In addition, individuals with learning disabilities
and/or speech delays, with or without behavior problems, al-
though not mentally retarded, are also more likely to have chro-
mosomeabnormalities,particularly47,XXX,47,XXY,or47,XYY.
Chromosome abnormalities are also found in approximately 5%
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650 Genetics IN Medicineof individuals with autism, usually in association with MR/DD.15
Thus,cytogeneticstudiescanrevealthecauseinasubstantialpro-
portion of cases of MR/DD.
AnaccuratediagnosisforMR/DDisvaluableforthepatient
andthepatient’sfamilyaswellasforhealthcareproviders.An
early diagnosis can elucidate the recurrence risk for parents,
especially those carrying chromosome rearrangements. Ther-
apeutic strategies can be investigated more easily, appropriate
counseling and intervention issues can be addressed, and im-
portantdiagnosticandtreatmentinformationcanbeprovided
to schools and care providers.1
A set of guidelines for diagnosis and genetic testing would be
useful,giventhevarietyandcomplexityofcausesofMR/DD,and
thebenefitsofanaccuratediagnosis.Thefollowingaretherecom-
mendations of the American College of Medical Genetics
(ACMG)ProfessionalPracticeandGuidelinesCommittee,which
was convened to assist health care professionals in making deci-
sions regarding cytogenetic diagnostic testing and counseling for
MR/DD. This document reviews available evidence concerning
the value of conventional and molecular cytogenetic testing for
the identification of chromosomal anomalies that play a role in
the etiology of MR/DD, and, based on this evidence, specific rec-
ommendations for each method of testing are provided.
RECOMMENDATIONS FOR TESTING
Routine chromosome analysis
Historically, when investigating an individual with MR or
DD, with or without dysmorphic features, the initial analysis
began with routine chromosome analysis of peripheral blood.
Developed in the 1970s, G-banding and other chromosome
bandingtechniquespermittheidentificationofthealternating
light and dark staining bands comprising each chromosome,
the detection of aneuploidy (extra or missing chromosomes),
and the identification of microscopically apparent structural
aberrations, including deletions and translocations. The rou-
tine G-banding level of blood chromosome analysis is in the
range of 400-550 bands per haploid karyotype; however, for
patientswithMRordevelopmentaldelay,constitutionalstud-
ies with banding levels of  550 should be repeated (ACMG
Standards and Guidelines for Clinical Genetics Laboratories,
Section E5.1.1.4). Banding techniques are routine procedures
in clinical cytogenetic laboratories and are important in the
evaluation of all individuals with MR or developmental delay
regardless of the presence of dysmorphic features, small stat-
ure, congenital abnormalities, or unusual or manneristic be-
havior. It should not be assumed that perinatal distress and
delivery complications are adequate to explain subsequent de-
velopmental delay and MR, because these complications can
be associated with chromosome abnormalities. Based on good
and consistent evidence, the overall yield of routine cytoge-
netic testing is 3.7%.6
High-resolution chromosome analysis
Because the chromosomal alterations that result in MR/DD
frequentlyareundetectableatthelevelofresolutionofroutine
chromosomal analysis, high-resolution analysis may be re-
quired to detect microdeletions, microduplications, or subtle
translocations in the individual with MR/DD. Rather than us-
ing cells in mid-metaphase, which display bands that have
fused during contraction, high-resolution chromosomal anal-
ysis involves the synchronization of lymphocyte cultures to
achieve a population of cells in prophase or prometaphase.16
Whereas the metaphase cells used in conventional chromo-
somal analysis yield approximately 400-550 bands per haploid
genome, prophase or prometaphase preparations enable the
visualization of up to 1000 bands.17 Because of the increased
numberofvisiblebands,smallstructuralchromosomalabnor-
malities such as deletions or duplications not resolvable with
standard karyotypes may be detected. The ACMG Standards
and Guidelines for Clinical Genetics Laboratories recommends
that a focused high-resolution analysis should be reserved for
cases in which a specific microabnormality syndrome is being
considered,thediagnosisofwhichgenerallyrequireschromo-
somes above the 650-band stage (resolution at the 850-band
levelmaybenecessary).Inaddition,completehigh-resolution
chromosome analysis should always include a minimum of
three pairs of each chromosome at a level of resolution above
the650-bandstage.However,becauseoftheincreasedamount
ofworkrequiredandthedifficultyofhigh-resolutionchromo-
somalanalysis,routinelyachievingapproximately850bandsis
usually reserved for targeting specific chromosomal regions.18
At resolutions  650 bands, alterations as small as 3-5 Mb can
be reliably detected using chromosome analysis on peripheral
blood; for the detection of subtle rearrangements in patients
witheitherabnormalornormalkaryotypes,molecularcytoge-
netic analysis may be useful.
Molecular cytogenetic analysis
For individuals with MR/DD and phenotypes suggestive of
particular disorders, targeted fluorescence in situ hybridiza-
tion(FISH)canbeperformedpriortoorconcurrentwithrou-
tinechromosomeanalysisifaparticularmicrodeletion/micro-
duplication syndrome is under consideration. FISH involves
the hybridization of fluorescently labeled DNA probes to the
denaturedDNAofmetaphasechromosomesorinterphasenu-
clei directly on a glass slide.19–21 Types of DNA probes include
unique sequence probes such as:
● bacterial artificial chromosome (BAC) clones, yeast arti-
ficial chromosome (YAC) clones, and cosmid clones that
are used to interrogate a specific locus on a chromosome;
● repetitive sequence probes, such as alpha-satellite se-
quences to identify the centromeric regions of individual
chromosomes; or
● whole-chromosome painting (WCP) probes, which uti-
lize chromosomal libraries of clones for hybridization
along the length of a specific chromosome.
FISH is capable of detecting submicroscopic (5M b )
alterationsthatcannotbereliablyobservedusingroutineor
high-resolutionmicroscopicchromosomeanalysis.Resolu-
tion by FISH is dictated by the size of the probes used. For
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mately 30 to 40 kb, while contigs of overlapping cosmids or
BAC probes provide a resolution of 80 to 200 kb.18 The
importance of FISH is illustrated by its use in detecting
submicroscopic rearrangements in numerous microdele-
tion syndromes, including those with a relatively high fre-
quency in the general population (e.g., DiGeorge/velocar-
diofacial syndrome, approximately 1:400022), and some
microduplicationsyndromes(e.g.,dup(17)(p11.2p11.2)23).
However, because FISH relies upon the use of location-
specific probes, it can only be used when the phenotype
suggests a particular disorder so a specific probe can be
requested. If locus-specific FISH analyses reveal abnormal-
ities, FISH should also be performed on both parents to
identify a carrier parent. FISH screening on patients with
moderate to severe MR/DD has been shown to have a rela-
tively high yield of 6.8%.6
Subtelomeric analysis
Because idiopathic MR/DD accounts for a significant pro-
portion of MR/DD cases—approximately 40% of moderate to
severe MR/DD11 and 45% to 65% of mild MR/DD24—and
because most of these individuals do not have a specific phe-
notype that would indicate the use of a locus-specific probe,
locus-specific FISH is not feasible for most initial attempts at
diagnosis.However,evidenceexiststhataberrationsintheter-
minal bands of chromosomes, the subtelomeric regions, are
the cause of many cases of idiopathic MR/DD. Although re-
portsofsubtelomericaberrationsinunexplainedMR/DDvary
by their inclusion criteria, number and type of subjects, and
testing acumen, it is estimated that approximately 5% of un-
explained cases of MR/DD can be attributed to alterations of
the subtelomeric regions.13,14,25 This is because the subtelo-
meric regions are relatively gene-rich,26 with alterations in
these regions predicted to be more likely to result in abnormal
phenotypes,andarebelievedtobepronetorearrangementdue
to a number of mechanisms.27,28 Because the ends of chromo-
somes lack distinctive G-bands, it is difficult to see small rear-
rangements at these regions in routine karyotype analysis and
sometimes even at higher resolution (850-band). Further-
more,thepresenceofrepetitivesequenceswithinthetelomeric
regions precludes the use of chromosome-specific telomeric
probes for FISH analysis due to the potential for multiple hy-
bridization signals. However, the development of a set of 41
unique subtelomere probes (the short arms of the acrocentric
chromosomes are not represented, and the X/Yp and X/Yq
pseudoautosomal regions are represented by one clone
each)29,30haspermittedanalysisoftheuniqueregionsapprox-
imately 300 kb proximal to the repetitive telomere region.
Thedegreeofdevelopmentaldelay/mentalretardationor
learning disability is a major predictor of the likelihood of
finding a subtelomeric rearrangement as the cause of
the individual’s disorder. Those with moderate or severe
MR/DD and a small chromosomal abnormality are more
likely to have some combination of facial dysmorphism,
minor physical abnormalities of the hands or feet, small
stature, and/or microcephaly. The finding of MR/DD and
anabnormalphenotypeinarelativeincreasesthechancesof
detecting a small chromosomal rearrangement.31 Recently,
a set of clinical criteria for subtelomere screening was
proposed32 that may be helpful in some cases. The authors
concluded that good indicators for subtelomeric defects are
positive family history, prenatal-onset growth retardation,
postnatal poor growth/overgrowth, two or more facial dys-
morphic features, and one or more nonfacial dysmorphic
features and/or congenital abnormalities.32 If subtelomere
FISH analyses reveal abnormalities, FISH should also
be performed on both parents to establish the parental ori-
gin of the anomaly and exclude the possibility of
polymorphism.33,34
Subsequent testing after finding a structural chromosome
abnormality
After initial testing, if the patient’s chromosomes display a
structural abnormality, chromosome analysis should be per-
formed on both parents to determine whether one of them
carries a balanced rearrangement. If a carrier parent is de-
tected,thenatureoftherearrangementshouldbecomeclear.If
parental chromosomes are normal, several molecular cytoge-
netic techniques, used alone or in tandem (e.g., FISH using
WCP probes or subtelomere probes) can be used to define the
patient’s rearrangement.
In addition, techniques have been developed to differentially
labeleachhumanchromosomewithauniquecolorcombination
to obtain 24-color karyotypes.35–38 This allows the detection of
structuralchromosomalaberrationsatalevelofresolutionsimilar
tothatofaroutinekaryotype(400to550bands).However,these
techniques cannot detect rearrangements involving only a single
chromosome such as deletions, inversions, and intrachromo-
somal duplications, and the limited number of spectrally resolv-
able fluorochromes may prohibit accurate detection of some
translocations.39 Thus, 24-color karyotyping is usually used in
conjunction with other procedures (e.g., subtelomere FISH) to
maximize effectiveness.
Subsequent testing options if no chromosome abnormality is
found
Direct DNA analysis for the fragile X syndrome is indicated
in addition to chromosome analysis for all developmentally
delayed/mentally retarded individuals, both male and female,
whodonothaveanapparentunderlyingcausefortheirclinical
status such as microcephaly, craniofacial dysmorphism and
multiple congenital abnormalities.40 Both chromosome anal-
ysis and fragile X DNA analysis should be performed because
chromosome abnormalities are as common, or more com-
mon, than fragile X mutations in mentally retarded individu-
als. ACMG recommendations for diagnostic testing for fragile
X syndrome, a significant inherited cause of MR/DD, have
been published previously.40 The overall yield of abnormal re-
sults after fragile X testing is 2.6%.6
If, after initial testing by karyotyping and molecular cytoge-
neticsthepatient’schromosomeanalysisrevealsnoabnormal-
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main. Comparative genomic hybridization (CGH) is one
possible option. In this technique, two genomes are differen-
tially labeled and directly compared by simultaneous hybrid-
ization to normal metaphase chromosomes. It has an average
resolution of approximately 10 Mb in most laboratories,41–43
although higher resolutions have been reported.44 However,
for most laboratories the low resolution precludes its useful-
ness. The future application of CGH is on microarrays (array
CGH), in which the two differentially labeled genomes are
compared using large-insert clones immobilized on a glass
slide as the substrates for analysis.45,46 With this technique the
resolution is substantially increased over conventional cytoge-
netics, depending on the size and density of clones used. It is
likely that for certain applications, such as the individual with
nonspecific MR/DD, array CGH may be used in conjunction
with routine cytogenetics to replace the locus-specific and/or
subtelomere FISH in the future.47
Analysis of tissues other than blood
The routine and molecular cytogenetic analyses outlined
thus far are usually performed on peripheral blood. However,
therearesomesituationsinwhichthecytogeneticanalysisofa
skin biopsy or other tissue may be indicated. First is the anal-
ysis of a different tissue type in T-cell deficient individuals.
Because the analysis of metaphase chromosomes requires
stimulation of T-cells by a mitogen (phytohemagglutinin) to
enter mitosis, some individuals, such as those with DiGeorge
syndrome, may not have enough normal T-cells to yield ade-
quate metaphases for analysis. In these cases, skin fibroblast
cultures, which do not depend on phytohemagglutinin stimu-
lation, can be used to evaluate the chromosomes.
A second example is the cytogenetic analysis of skin fibro-
blasts to detect mosaicism. Current standard methods for cy-
togenetic analysis of peripheral blood will identify only those
chromosome aberrations that are present in the circulating
T-lymphocytes. However, there are certain chromosome ab-
normalities that do not appear to be compatible with survival
of the T-cells.48 Therefore, only those T-cells that do not con-
tain the aberration will be present in the circulating lympho-
cytes. Examples of this include mosaic tetrasomy of the short
arm of chromosome 12 (Pallister-Killian syndrome49,50) and
mosaic trisomy 17.51
Finally, the chromosomal aberration simply may not be
present in the peripheral blood because of tissue-limited
mosaicism.51 In cases in which chromosomal analysis is nor-
malbutsuspicionofachromosomeabnormalityremainshigh,
a skin fibroblast culture can be used to detect the aberration.
Skin biopsies may be taken from individuals with asymmetry
or individuals with hypo- and hyperpigmented regions. The
skinshouldbecleansedwithalcoholandnotwithiodine-con-
taining compounds because these inhibit cell growth in cul-
ture. Chromosome analysis of skin biopsies has been used to
study parents who have more than one child with the same
chromosome aberration, e.g., trisomy 21.52 Case reports sug-
gestthatcytogeneticanalysisofskinbiopsiesisapossiblealter-
native when chromosome analysis of blood is normal, al-
though the yield is unknown. Studies using series of patients
are needed to determine the overall yield for finding a cytoge-
netic diagnosis using skin biopsies.
Analysis when fetal karyotype is normal following prenatal
diagnosis
In cases of developmental delay or MR, with or without
physicalanomalies,andinnewbornswithdysmorphicfeatures
and/or multiple malformations, a blood karyotype should be
performed even when a fetal karyotype from amniocentesis or
chorionic villus sampling is normal. There are several reasons
to perform a blood karyotype. First, there may be mosaicism
that has gone undetected in the fetal analysis. Second, the
banding resolution is often higher in postnatal blood prepara-
tionsthaninculturedamniocytesorchorionicvilli.Finally,the
majority of fetal chromosome analyses are done for general
reasons (e.g., advanced maternal age, abnormal triple-marker
screening) and not for a specific set of dysmorphic features.
After birth, the clinical features may provide clues regarding a
specific chromosomal imbalance or for the use of additional
techniques (e.g., FISH).
Summary of Recommendations
● For any child with unexplained MR/DD, even in the ab-
senceofdysmorphicfacialfeatures,otherclinicalfeatures
or positive family history, routine chromosome analysis
(minimum 550-band resolution) is indicated.
● For children with clinical features of known chromo-
somal abnormality syndromes (e.g., Down syndrome),
cytogenetic analysis should be performed. The identifica-
tion of a translocation may affect the family’s recurrence
risk.
● High-resolutionchromosomeanalysisisnotroutinelyin-
dicated unless a specific chromosomal region is to be in-
vestigated or there is a family history of a particular ab-
normality. These studies should be limited in focus and
used when FISH is not available.
● For children with clinical features suggestive of a particu-
lar microdeletion/microduplication syndrome, FISH or
othermoleculartechniquesshouldbeperformedpriorto
or concurrently with chromosome analysis.
● Ifchromosomeanalysisisnormalat550-bandresolution,
subtelomere FISH testing may be considered.
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